ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma

INTRODUCTION: Omalizumab is a novel anti-IgE therapy for patients having inadequately controlled severe persistent allergic asthma with uncontrolled symptoms despite GINA 2002 step 4 therapy (inhaled ICS + LABA∓ additional controller medication as necessary). Omalizumab reduces exacerbations in thes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prim Care Respir J
Autors principals: Price, D., Fox, H., Ayre, G., Blogg, M., Massanari, M., Reisner, C.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2006
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6730752/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.136
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars